News

(RTTNews) - Abeona Therapeutics Inc. (ABEO) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved ZEVASKYN, the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease.

There is no cure for RDEB and ZEVASKYN is the only FDA-approved product to treat RDEB wounds with a single application, the company noted.

The approval is based on the Phase 3 VIITAL study that showed statistically significant healing of 50 percent or more from baseline in large chronic RDEB wounds, and pain reduction as evaluated at six months after treatment.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.